|Articles|March 1, 2006
- Pharmaceutical Executive-03-01-2006
- Volume 0
- Issue 0
South Africa
Author(s)Frederic Boucheseiche, Kirsten Craze
Sponsored and produced by Focus Reports.
Advertisement
Articles in this issue
over 20 years ago
Global Report: Chemicals Legislation in Europeover 20 years ago
Pharma's Next Top Model: Slimmer Business Modelsover 20 years ago
Market Research Roundtableover 20 years ago
Holding Their Breath: Inhaled Insulinover 20 years ago
Sales Management: Spending Under Scrutinyover 20 years ago
Genzyme: The Price of Successover 20 years ago
Invisible Prescribers: What You Do and Don't Know About NPs and PAsover 20 years ago
From the Editor: Fine Whinesover 20 years ago
Legal: Hey, Good Lookin': Sex Discrimination in Hiring Repsover 20 years ago
Thought Leader: Q&A with Hugo StephensonAdvertisement
Related Content
Advertisement
Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5